BD completed the acquisition of the Critical Care Product Group of Edwards Lifesciences for $4.2bn.

BD, a global medical technology company, completed the acquisition of the Critical Care Product Group of Edwards Lifesciences, a provider of advanced monitoring solutions, for $4.2bn. "Critical Care expands BD's portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement BD's existing technologies serving operating rooms and intensive care units," Tom Polen, BD Chairman, CEO and President.